


April 6-8, 2026 | Boston, MA



5th Annual

LNP Formulation & Process Development Summit

Advancing Specific, Stable, & Scalable LNPs from Concept to Market

Discover, Formulate, & Manufacture Targeted, Stable, & Selective LNPs for mRNA, gRNA, CAR DNA & Beyond to Ensure Safety & Efficacy of Therapeutics Across Indications

60+ World-Class Speakers, Including:



Annette Bak
Head, Advanced Drug
Delivery
AstraZeneca



Luis Brito
Vice President,
Delivery Platform
Beam Therapeutics



Adrian Bot
Ex-Chief Scientific
Officer & Executive Vice
President, Research &
Development
Capstan Therapeutics



Rushit Lodaya
Associate Director,
RNA Delivery Sciences
GSK



Michael Smith
Director, Emerging
Technologies
Moderna



Ching Kim Tye
Head, Drug Product
Platform & Early
Clinical Development
Sanofi



Isabelle Gusev
Principal Scientist
& Group Leader,
Analytical
Development, CMC
Tessera Therapeutics



Peng Zhang
Principal Scientist,
Science - Excipients
USP



Emma Wang
Chief Technology
Officer
Yo!Tech Therapeutics



250+
LNP Expert Attendees



50+
Data-Driven Case Studies



3
Parallel Tracks of Talks
for You & Your Team



1
Unmissable Event

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

Proud to
Partner With:



serina
therapeutics



REGISTER
NOW

Welcome to the Ultimate Industry-Led Lipid Nanoparticle Event!

Billions of dollars are exchanging hands for LNPs with **AbbVie's acquisition of Capstan Therapeutics** for CAR-TCR technology, **Lilly's purchase of Verve Therapeutics** for gene-editing technology and **BMS' buyout of Orbital Therapeutics** for next generation CAR T-cell therapy. It's clear that LNPs are in the lead as the non-viral delivery system of choice for big pharma players.

The **5th LNP Formulation & Process Development Summit** returns to unite industry leaders dedicated to advancing LNP research and development. Across 3 days of cutting-edge content and 60+ speakers from large pharma and pioneering biotech, the 2026 agenda spans 3 parallel tracks, **Analytical Development & Characterization**, **Formulation & Delivery** and **Process Development & Manufacturing**. Topics include:

- Exploring analytical strategies across modalities with robust techniques in particle size, encapsulation efficiency, and stability profiling to enable more accurate and reproducible characterization of LNP systems
- Optimizing lipid compositions and targeting strategies to deliver mRNA, cell therapy, and gene editing payloads beyond the liver with specificity and selectivity
- Advancing LNP manufacturing processes from the get-go to streamline your transition from preclinical to clinical and commercial scale with GMP compliance

Curated in collaboration with a world-class **Scientific Advisory Board**, consisting of **AstraZeneca**, **Beam Therapeutics** and **Sanofi**, this is your end-to-end, industry-led LNP event. Join the LNP field in April 2026 to hear ground-breaking data and next-generation innovations to **fast-track your LNP-mediated therapeutics and vaccines towards the patients in need**.

Meet the Expert Scientific Advisory Board



Building on the success of last year, the **5th LNP Formulation & Process Development Summit** is once again guided by an esteemed Scientific Advisory Board, whose expertise continues to shape a world-class program of scientific excellence and innovation.



Annette Bak
Head, Advanced Drug
Delivery
AstraZeneca



Luis Brito
Vice President, Delivery
Platform
Beam Therapeutics



Ching Kim Tye
Head, Drug Product
Platform & Early Clinical
Development
Sanofi

■ This Summit showcases the latest advances in LNP formulation, analytical characterization, and process development, addressing key challenges such as extrahepatic targeting, immunogenicity, and scalable manufacturing. The program's focus on integrating novel lipid chemistries, high-throughput analytics, and automation is important for the translation of RNA and gene editing therapies towards the clinic ■

Annette Bak, Head, Advanced Drug Delivery,
AstraZeneca

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

2

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



What's New in 2026?

Brand New Companies Speaking

YolTech
THERAPEUTICS

GSK

MERCK

Alnylam
PHARMACEUTICALS

REGENERON

moderna

Johnson & Johnson

SERVIER
moved by you

alltrna

CORNER
THERAPEUTICS

LNP Acquisitions & Investments

Amid a surge of high-value deals across the LNP landscape in 2025, we've brought together a panel discussion consisting of investment experts and industry leaders to unpack the strategic motivations driving recent acquisitions and partnerships within the LNP community.



Adrian Bot
Ex-Chief Scientific
Officer & Executive Vice
President of Research
& Development
Capstan Therapeutics



Issi Rozen
General
Partner
GV



Ester Caffarel-Salvador
Director, Strategic
Innovation
**Chiesi Global
Rare Diseases**



Rajul Jain
Managing
Director
**Vida
Ventures**

Achieving Extrahepatic Targeting with LNP Formulations

Discover how the LNP field is evolving beyond traditional formulations as the 2026 Summit showcases ground-breaking approaches to targeted delivery and innovative formulations enabling extrahepatic applications. Learn from leading experts pioneering next-generation LNPs that unlock new therapeutic opportunities across diverse tissues and disease areas.



Jamie Tsung
Director, Drug Product
Formulation, CMC
Development
Alnylam



Amit Singh
Director, Delivery
Discovery
Mote Therapeutics



Hongjing Xia
Principal Scientist II
Novartis



Daryl Drummond
Chief Scientific Officer
Akagera Medicines



Zach Zhu
Chief Technology Officer
Innorna

Your End-to-End Roadmap for LNP Development

Track A - Analytical Development & Characterization: Building High-Quality & Consistent LNPs



**Workshop B: Achieving
Targeted LNP Uniformity
by Incorporating Advanced
Analytics for Ligand
Quantification & Stability**

**Employing High
Throughput, Semi-
Automated Analytical
Strategies to Accelerate
LNP Formulation
Optimization**

**De-Risking LNP Stability
through Advanced
Analytical Strategies to
Monitor Degradation &
Optimize Shelf-Life**



Track B - Formulation & Delivery: Innovating Targeted & Extrahepatic LNP Design



**Engineering LNPs to
Detarget the Liver by
Balancing Circulation Time
& Targetability for More
Efficacious Drug Products**

**In Vivo Genome Editing:
Translating Science from
Bench to Bedside**

**Workshop C: Engineering
Specific & Selective LNPs
for Brain & Muscle Targeting
to Treat a Wider Array of
Diseases**



Track C - Process Development & Manufacturing: Scaling LNPs from Research to Commercialization



**Refining Lyophilization
Processes to Preserve LNP
Quality & Morphology for
Enhanced Stability & Shelf-
Life**

**LNP Particle Size Control:
Effect of RNA Type, Buffer &
Process Parameters**

**Optimizing TFF by
Incorporating Membrane
Screening & In-Process
Analytics to Enhance Buffer
Exchange & Concentration**



REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

3

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Agenda at a Glance

5th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

REGISTER
NOW

PRE-CONFERENCE DAY Monday, April 6	
LNP 101 Day	Workshop Day
Introducing the Discovery of LNPs & Novel Targeting Strategies	Workshop A: Fast-Tracking Ligand Selection with Robust High Throughput Screening
Morning Networking Break	
Spotlighting the Foundations of Formulation, Process Development & Manufacturing	Workshop B: Achieving tLNP Uniformity by Incorporating Advanced Analytics
Lunch & Networking Break	
Overcoming Bottlenecks of IP, Toxicity & Batch-to-Batch Variability	Workshop C: Engineering Specific & Selective LNPs for Brain & Muscle Targeting
Afternoon Networking Break	
End of LNP 101 Day	Workshop D: Solving the Immunogenicity Problem to Enable Repeat Dosing
End of Pre-Conference Day	

CONFERENCE DAY ONE Tuesday, April 7		
Driving Translational & Strategic Success by Leveraging Investment & Next Generation Insights		
Morning Break & Speed Networking		
Track A: Analytical Development & Characterization	Track B: Formulation & Delivery	Track C: Process Development & Manufacturing
Leveraging Heightened Characterization to Optimize LNP Properties	Innovating Ionizable Lipid Design to Enhance mRNA Vaccine Delivery	Optimizing Buffer Choices & Lyophilization Processes
Lunch & Networking Break		
Advancing Potency Assessment to Improve <i>In Vitro/In Vivo</i> Translation	Redesigning LNPs to Achieve Extrahepatic Targeting	Achieving Large Scale Targeted LNP Manufacturing
Afternoon Networking Break		
Strengthening LNP Stability with Robust Analytical Strategies	Uncovering AI-Driven Design & Ionizable-Lipid-Free Formulations	Elevating TFF with Advanced Membranes & Analytical Strategies
End of Conference Day One		

CONFERENCE DAY TWO Wednesday, April 8		
Pushing the Boundaries of LNP Formulations to Advance Extrahepatic Targeting		
Morning Break & Speed Networking		
Track A: Analytical Development & Characterization	Track B: Formulation & Delivery	Track C: Process Development & Manufacturing
Harnessing Analytics to Assess Excipients, Raw Materials & Solvents	Transforming LNP Formulations for Genome Editing	Controlling Particle Size & De-risking Batch-to-Batch Variability
Lunch & Networking Break		
Optimizing LNP Characterization with High Throughput & Orthogonal Analytics	Revolutionizing Ligand Design & Selection for Precise Targeting	Scaling Smartly to Produce High-Quality & Consistent LNPs
Afternoon Networking Break		
Advancing Cutting Edge LNP Platforms for Precise & Safe Delivery of Gene & Cell Therapies		
End of the 5th LNP Formulation & Process Development Summit		

Your 60+ Expert Speakers

5th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

World-Class Scientific Advisory Board



Annette Bak
Head, Advanced Drug
Delivery
AstraZeneca



Luis Brito
Vice President, Delivery
Platform
Beam Therapeutics



Ching Kim Tye
Head, Drug Product
Platform & Early Clinical
Development
Sanofi

■ An excellent opportunity to participate
with experts of all types in the LNP field! ■
Scientist II, Nucleic Acid Delivery,
Novo Nordisk

Industry Leaders from Big Pharma:




Liping Zhou
Senior Director,
Advanced Drug Delivery
AstraZeneca



Ester Caffarel-Salvador
Director, Strategic
Innovation
**Chiesi Global Rare
Diseases**



Daniel Estabrook
Senior Advisor,
Bioproduct Research &
Development
Eli Lilly & Co



Rushit Lodaya
Associate Director, RNA
Delivery Sciences
GSK



Bader Jarai
Principal Scientist, Drug
Product Development &
Delivery
**Johnson & Johnson
Innovative Medicine**



James Deng
Associate Principal
Scientist, Vaccine
Analytical Research &
Development
Merck & Co



Hongjing Xia
Principal Scientist II
Novartis



Matthew Eastwood
Scientist II, Nucleic Acid
Delivery
Novo Nordisk



Shruti Trivedi
Scientist,
Pharmaceutical
Research &
Development
Pfizer



Aishwarya Saraswat
Senior Scientist,
Formulation
Development Group
Regeneron



Eric Holowka
Associate Director, Drug
Delivery Innovation
Regeneron



Natalya Martin
Principal Scientist,
Biochemistry &
Biophysics, Analytical
Development
Sanofi



Saikat Manna
Senior Scientist,
Delivery & Formulation
Sanofi



Saswata Karmakar
Director, Platform
Chemistry
Sanofi



Geoffrey Prévot
Scientist, Early
Formulation & Drug
Profiling
Servier



Raquib Hasan
Senior Scientist,
Advanced Technologies,
Drug Product
Development
Takeda

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

5

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



LNP Innovators from Biotech & Academia:

5th Annual LNP Formulation & Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US


PRICING &
DISCOUNTS



REGISTER
NOW



Bo Ying
Chief Executive Officer
Abogen Biosciences



Daryl Drummond
Chief Scientific Officer
Akagera Medicines



Harsh Chauhan
Director, Formulation
Development & External
Manufacturing
Alltrna



Jamie Tsung
Director, Drug Product
Formulation, CMC
Development
Alnylam



Shengshuang Zhu
Senior Principal Scientist
Arbor Biotech



Brenda Star Clemente
Director, Drug Product
Process Development
Arcturus Therapeutics



Kinkini Roy
Associate Director,
Formulation & Drug
Product Development
Aviceda Therapeutics



Ronen Eavri
Chief Executive Officer &
Co-Founder
Barcode Nanotech



Delai Chen
Director, Nanoparticle
Formulation
Beam Therapeutics



Morgan Urello
Principal Scientist,
Nucleic Acid Delivery
Biotech Startup




Arnab Rudra
Visiting Scientist
**Boston Children's
Hospital**



Adrian Bot
Ex-Chief Scientific
Officer & Executive Vice
President, Research &
Development
Capstan Therapeutics



Andrew Cornforth
Chief Technology Officer
Corner Therapeutics



Mercedes Segura Gally
Vice President, Process
Development
Editas Medicines



Urmi Chheda
Senior Process Engineer
Editas Medicines



Issi Rozen
General Partner
GV



Zach Zhu
Chief Technology Officer
Innorna



Roger Adami
Chief Technology Officer
Land Therapeutics



Michael Smith
Director, Emerging
Technologies
Moderna



Amit Singh
Director, Delivery
Discovery
Mote Therapeutics



Padma Malyala
Chief Technology Officer
nChroma Bio



Jennifer Zachry
Co-Founder, Director,
Business Development
Orion Therapeutics



Douglas Scott
Scientist II, LNP
Formulation & Process
Development
Prime Medicine



Dan Shores
Partner
Rothwell Figg

LNP Innovators from Biotech & Academia:

5th Annual LNP Formulation & Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US


PRICING &
DISCOUNTS



REGISTER
NOW



Lokesh Narsineni
Senior Scientist,
Process Sciences
Scribe Therapeutics



**Matthew Reynolds-
Tejeda**
Senior Associate
Scientist, Nanoparticle
Process Development
Strand Therapeutics



Isabelle Gusev
Principal Scientist &
Group Leader, Analytical
Development, CMC
Tessera Therapeutics



Evan Williams
Professor
University of
California, Berkeley



Anni Chang
Senior Scientist II
USP



Peng Zhang
Principal Scientist,
Science – Excipients
USP



Rajul Jain
Managing Director
Vida Ventures



Emma Wang
Chief Technology Officer
Yoltech Therapeutics



Andrzej Pitek
Delivery Expert

■ This meeting has become the industry leading event to highlight next generation LNP technology, both from a fundamental formulation perspective and from the manufacturing and scale-up perspective ■

Chief Technology Officer, **Land Therapeutics**

Pioneering Partners:



Pre-Conference LNP 101 Day

Monday, April 6



Providing an Introduction into Targeted LNPs for Organ & Cell-Specific Delivery Beyond the Liver

Roger Adami, Chief Technology Officer,
Land Therapeutics



An Overview of the Intellectual Property Trends for LNPs Including New Targeting Technologies

Dan Shores, Partner, Rothwell Figg

■ Fostering a culture of continuous learning and innovation is essential for advancing LNP-based therapeutics. ■

Principal Scientist, **Sanofi**

8th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

The **LNP 101 Day** is designed to provide a comprehensive introduction into the fundamentals of LNP biology, formulation, process development and manufacturing, ensuring you have a solid understanding of the key concepts behind successful LNP development. Whether you're new to LNPs or simply looking to refresh your foundational knowledge, this is a great opportunity to provide you with the confidence and context needed to kickstart your event experience.

Morning Agenda

- ➔ Deep dive into the discovery and evolution of LNPs
- ➔ Hear an introduction into formulating targeted LNPs for extrahepatic delivery
- ➔ Understand the foundations of successful LNP formulation, process development and manufacturing

12.30 PM Lunch & Networking

Afternoon Agenda

- ➔ Gain an insight into the intellectual property trends for targeted LNPs
- ➔ Overcome the common but critical challenges which arise during LNP development
- ➔ Evaluate how LNPs circulate and distribute after administration

sanofi

Beam
THERAPEUTICS

alltrna

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

8

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development

hansonwade

Pre-Conference - LNP 101 Day | Monday, April 6

8th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

REGISTER
NOW



8.00 Registration Opens & Morning Coffee



Kinkini Roy
Associate Director,
Formulation & Drug Product
Development
Aviceda Therapeutics

8.50 Chair's Opening Remarks

Introducing the Discovery of LNPs & Novel Targeting Strategies to Achieve Extrahepatic Delivery for Enhanced Therapeutic Impact

9.00 Fireside Chat: Delving into the Discovery & Evolution of LNPs to Gain an Understanding of the Foundation & Future Potential for LNP Delivery

- Uncovering the origins of LNP technology and how they were initially discovered
- Exploring the evolving role of LNPs from early gene delivery systems to their pivotal role in mRNA vaccine development
- Showcasing the key scientific breakthroughs that have shaped modern LNP design



Shengshuang Zhu
Senior Principal Scientist
Arbor Biotech



Saswata Karmakar
Director, Platform Chemistry
Sanofi



Roger Adami
Chief Technology Officer
Land Therapeutics

9.30

NEW
COMPANY

Providing an Introduction into Targeted LNPs for Organ & Cell-Specific Delivery Beyond the Liver

- Diving into the fundamentals of targeted LNP design, including ligand selection and surface modifications
- Reviewing the biological and formulation factors that influence tissue and cell specificity
- Analyzing current applications and early strategies used to enhance precision and reduce off-target effects



10.00 Morning Networking Break

Spotlighting the Foundations of Formulation, Process Development & Manufacturing to Establish Robust, Scalable Pathways for High Quality LNP Development



Kinkini Roy
Associate Director,
Formulation & Drug Product
Development
Aviceda Therapeutics

11.00 Deep Diving into LNP Formulations to Uncover How Lipid Chemistry Shapes Effective Delivery & Therapeutic Success

- Breaking down the key components of LNPs, focusing on the functional roles of ionizable lipids, helper lipids, cholesterol, and PEG-lipids
- Examining the principles of designing ionizable lipids to learn what makes them effective
- Understanding how formulations are tailored to optimize stability, delivery efficiency, and payload compatibility



Delai Chen
Director, Nanoparticle
Formulation
Beam Therapeutics

11.30 Optimizing Pharmaceutical Properties of LNPs by Improving Composition & Components for Greater Potency

- Fine-tuning the structure and ratio of lipids to boost LNP delivery efficiency
- Tailoring the cargo to unlock higher efficacy
- Demonstrating how process optimization strengthens LNP stability, and ensures consistent pharmaceutical properties

9

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Pre-Conference - LNP 101 Day | Monday, April 6

8th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900



Harsh Chauhan
Director, Formulation
Development & External
Manufacturing
Alltrna

12.00

Building a Foundation on LNP Process Development & Manufacturing to Achieve Product Consistency & Scalability

NEW
COMPANY

- Showcasing the core steps in LNP process development to successfully translate from formulation to final product manufacturing
- Highlighting the key parameters to assess that influence product quality and the critical quality attributes
- Exploring fundamental strategies to ensure scalability, batch consistency, stability, and regulatory readiness



12.30 Lunch & Networking

Overcoming the Key Bottlenecks of IP, Toxicity & Batch-to-Batch Variability to Deliver Safe & Consistent LNP Drug Products for Improved Clinical Translation



Dan Shores
Partner
Rothwell Figg

1.30

An Overview of the Intellectual Property Trends for LNPs Including New Targeting Technologies

- Managing the crowded patent landscapes to secure and navigate third party rights relating to lipids, formulations, and delivery innovations
- Delving into the targeting moieties and other technologies which are driving and evolving the IP landscape
- Discussing the analytical framework for protecting the IP generated by research teams



Roger Adami
Chief Technology Officer
Land Therapeutics

2.00

Roundtable Discussion: Navigating Common but Critical Challenges Associated with LNPs to Build a Robust Toolkit for Developing Safe, Stable & Consistent LNPs



- Tackling common safety challenges of LNPs to enable redosability for more effective therapies
- Discussing the causes and impact of batch-to-batch variability and gaining insights into practical approaches for improving consistency
- Evaluating best practices for improving LNP stability and formulation to ensure global availability



Andrzej Pitek
Delivery Expert

3.00

Evaluating LNP Biology to Understand the Fundamental Properties that Impact Delivery Efficiency for Maximized Efficacy

- Deep diving into how LNPs circulate, distribute, and interact with biological systems after administration
- Exploring the key characteristics influencing biodistribution, cellular uptake, and endosomal escape
- Delving into how to measure LNP efficacy to evaluate therapeutic performance



Kinkini Roy
Associate Director,
Formulation & Drug Product
Development
Aviceda Therapeutics

3.30 Chair's Closing Remarks

3.45 End of LNP 101 Day

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

10

+ (1) 617 455 4188

@ info@hansonwade.com

www.lnp-formulation-process-development-pharma.com

in LNP Development



Pre-Conference Workshop Day Monday, April 6

Snapshot of Expert Workshop Leaders:



Mercedes Segura Gally
Vice President, Process Development
Editas Medicines



Jamie Tsung
Director, Drug Product Formulation, CMC
Development
Alnylam



Rushit Lodaya
Associate Director, RNA Delivery Sciences
GSK

■ This meeting provides a collaborative environment that not only accelerates scientific exchange but also helps align research efforts with real-world therapeutic needs, such as achieving efficient extrahepatic delivery ■

Scientist, **Servier**



8th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

During an interactive **Workshop Day**, LNP experts will share insights, case studies and solutions to the field's most critical challenges. Through deep-dive, discussion-based sessions, participants will have the opportunity to collaborate on topics ranging from achieving extrahepatic delivery to overcoming immunogenicity in order to expand the potential and application of LNPs.

Honing in on Four Key Areas:

- ➔ Uncovering rigorous screening strategies to accelerate lipid and ligand selection for enhancing
- ➔ Delving into advanced analytical methods for ligand quantification and stability assessment of targeted LNPs
- ➔ Designing selective LNPs to target the brain and muscle, expanding the therapeutic potential of LNP drug products
- ➔ Addressing the LNP immunogenicity challenge with novel analytics and formulations to support safe repeat dosing

Johnson & Johnson



REGENERON

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Pre-Conference Workshop Day | Monday, April 6

8th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

Registration Opens & Morning Coffee

7.30

Workshop A

8.00

Fast-Tracking Ligand & Lipid Selection with Robust Screening Strategies for Precise & Efficient Delivery

Building workflows to identify high performing targeting ligands and lipid components is essential for accelerating LNP development, however, ensuring speed is balanced with accuracy is vital. In this workshop, examine lipid type and ligand screening strategies and align these with complete targeted LNP formulations to enhance translation. Topics include:

- Exploring how to efficiently screen vast libraries of ligands for specificity, transfection, and immunogenicity
- Highlighting reliable strategies to identify lipids which will enable endosomal escape and extrahepatic delivery
- Improving targeted LNP screening to balance throughput with quality metrics like selectivity and safety

Workshop Leaders:



Aishwarya Saraswat
Senior Scientist,
Formulation Development
Group
Regeneron



Morgan Urello
Principal Scientist, Nucleic
Acid Delivery
Biotech Startup

Morning Networking Break

10.00

Workshop B

10.30

Achieving Targeted LNP Uniformity by Incorporating Advanced Analytics for Ligand Quantification & Stability

Targeted LNPs are continuing to advance and evolve to enable extrahepatic targeting. However, they are hindered by limited robust analytical strategies. During this workshop deep dive into reliable analytical methods for assessing ligand density, stability and aggregation for more consistent product quality. Topics include:

- Leveraging comprehensive analytics to quantify ligand density to determine uniformity and minimize heterogeneity
- Unlocking advanced analytical strategies to understand ligand stability, linker degradation and free ligands for safer targeted LNPs
- Implementing imaging techniques for assessing aggregation, structural integrity and surface functionalization

Workshop Leaders:



Matthew Eastwood
Scientist II, Nucleic Acid
Delivery
Novo Nordisk



Mercedes Segura Gally
Vice President, Process
Development
Editas Medicines

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

12

+ (1) 617 455 4188 @ info@hansonwade.com www.lnp-formulation-process-development-pharma.com LNP Development



Pre-Conference Workshop Day | Monday, April 6

8th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

Lunch & Networking

12.30

Workshop C

1.30

Engineering Specific & Selective LNPs for Brain & Muscle Targeting to Treat a Wider Array of Diseases

As the brain and muscle remain key targets for LNP drug products, this workshop will explore the hurdles of the blood-brain barrier and broad muscle biodistribution. Gain insights and have proactive discussions into how to optimize LNP formulations to achieve efficient, specific and selective delivery to muscle and CNS targets. Topics include:

- Examining how to fine-tune LNP characteristics to enable efficient delivery across extensive muscle areas without compromising immunogenicity
- Uncovering ligand approaches for achieving selective LNP penetration across the blood-brain barrier
- Evaluating how dual-targeting strategies may navigate endothelial barriers to deliver payloads into muscle and brain

Workshop Leaders:



Jamie Tsung
Director, Drug Product
Formulation, CMC
Development
Alnylam



Geoffrey Prévot
Scientist, Early
Formulation & Drug
Profiling
Servier

Afternoon Networking Break

3.30

Workshop D

4.00

Solving the Immunogenicity Problem by Leveraging Innovative Analytics & Formulations to Enable Repeat Dosing

With immune responses, from anti-PEG and ligand antibodies to component-linked immunogenicity, impacting LNP dosing regimens and limiting clinical success. This workshop will delve into advanced analytics for understanding safety and evaluate innovative solutions to achieve effective repeat dosing. Topics include:

- Highlighting analytical strategies to pinpoint the cause of limited repeat dosing, are PEG, targeting ligands, ionizable lipids, or linkers are to blame?
- Uncovering PEG alternatives that offer the most promise for preserving circulation time and transfection efficiency while reducing immunogenicity
- Unleashing novel ionizable lipids, targeting ligands, and linker chemistries which degrade quickly, enhance endosomal escape and improve safety

Workshop Leaders:



Rushit Lodaya
Associate Director, RNA
Delivery Sciences
GSK



Bader Jarai
Principal Scientist, Drug
Product Development &
Delivery
**Johnson & Johnson
Innovative Medicine**

End of Workshop Day

6.00

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

REGISTER
NOW

13

+ (1) 617 455 4188 @ info@hansonwade.com www.lnp-formulation-process-development-pharma.com LNP Development



Conference Day One

Tuesday, April 7

KEYNOTE SESSION:

Navigating Strategic Investments by
Harnessing Insights from Recent Acquisitions &
Collaborations within the LNP Field



Adrian Bot
Ex-Chief Scientific Officer & Executive Vice
President of Research & Development
Capstan Therapeutics



Ester Caffarel-Salvador
Director, Strategic Innovation
Chiesi Global Rare Diseases



Issi Rozen
General Partner
GV



Rajul Jain
Managing Director
Vida Ventures

Morning Plenary Session:

- ➔ Catalyzing translational and strategic success by leveraging investment and next generation insights

Analytical Development & Characterization Track

- ➔ Enhancing LNP morphology and encapsulation efficiency with advanced characterization techniques
- ➔ Refining potency evaluation to strengthen *in vitro/in vivo* correlation for greater clinical success
- ➔ Understanding LNP stability by leveraging robust analytical strategies

Formulation & Delivery Track

- ➔ Unlocking ionizable lipid innovations to boost mRNA vaccine delivery efficiency
- ➔ Broadening therapeutic application by reformulating LNPs to achieve extrahepatic targeting
- ➔ Advancing RNA delivery with AI-guided design and ionizable-lipid-free formulations

Process Development & Manufacturing Track

- ➔ Fine-tuning buffer systems and lyophilization processes to achieve ambient LNP storage
- ➔ Scaling up targeting LNP production by optimizing process and mixing strategies
- ➔ Enhancing TFF with novel membranes and analytical processes for greater LNP purity



CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW



7.30 Registration Opens & Morning Coffee

8.20 Chair's Opening Remarks

Driving Translational & Strategic Success by Leveraging Investment & Next Generation Insights to Fast-Track LNP Development



Adrian Bot
Ex-Chief Scientific Officer &
Executive Vice President of
Research & Development
Capstan Therapeutics

8.30 **Keynote Presentation: Engineering of the Immune System**

- Advancing Chimeric Antigen Receptor T-cell therapies: lessons learned from *ex vivo* engineered CAR T cell products
- Paving the way to *in vivo* generation of CAR-expressing immune cells: experience to date including viral and RNA-LNP based approaches
- The future of immunotherapy: bringing together precision medicine and nanotechnologies to advance safe, potent and tunable treatments for a broad range of disease categories



9.00 Session Reserved for Serina Therapeutics

9.30 **Panel Discussion: Navigating Strategic Investments by Harnessing Insights from Recent Acquisitions & Collaborations within the LNP Field**

- What are the driving factors behind recent deals, what are the unique aspects of LNP technology that investors are most focused on?
- What key factors do investors evaluate when assessing the potential and risks of LNP technologies?
- Beyond individual drug candidates, how do investors envision the broader potential and future impact of these LNP partnerships?



Adrian Bot
Ex-Chief Scientific Officer & Executive Vice
President of Research & Development
Capstan Therapeutics



Ester Caffarel-Salvador
Director, Strategic Innovation
Chiesi Global Rare Diseases



Issi Rozen
General Partner
GV



Rajul Jain
Managing Director
Vida Ventures



10.00 **Morning Break & Speed Networking**

This session is your opportunity to be face-to-face with many of the brightest minds working in the LNP field and establish meaningful business relationships to pursue for the rest of the conference. Also, don't forget to enjoy some refreshments before we split off into 3 different tracks:
Analytical Development & Characterization, **Formulation & Delivery** and **Process Development & Manufacturing**

Conference Day One | Tuesday, April 7

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

Analytical Development & Characterization Chair – Lokesh Narsineni, Senior Scientist, Process Sciences, Scribe Therapeutics	Formulation & Delivery	Process Development & Manufacturing
Leveraging Heightened Characterization Methods to Optimize LNP Morphology & Encapsulation for Improved Quality	Innovating Ionizable Lipid Design to Enhance Delivery Performance & LNP Stability for Improving mRNA Vaccines	Optimizing Buffer Choices & Lyophilization Processes to Improve LNP Stability for Ambient Temperature Storage
11.00 Molecular Characterization of Lipid Nanoparticles & mRNA Packaging with Single Particle Charge Detection Mass Spectrometry - Description of new mass spectrometry technology for analysis of intact particles with masses ranging from kDa to GDa - Applications to lipid nanoparticles to obtain accurate size distributions and mRNA packing - Fast characterization of lipid nanoparticle stability and future developments Evan Williams, Professor, University of California, Berkeley NEW DATA NEW COMPANY	11.00 Ionizable Lipids: The Secret Sauce of Effective mRNA Vaccines - Comprehensive analysis of lipid nanoparticle technology as the leading platform for mRNA vaccine delivery, examining current advancements and future directions - Strategic design and synthesis approaches for next-generation ionizable lipids that enhance mRNA delivery efficiency and cellular uptake - Systematic investigation of molecular architecture-function correlations in ionizable lipids to: - Enhance immunogenicity through improved antigen presentation - Minimize reactogenicity by reducing inflammatory responses - Improved thermostability of mRNA-LNPs for the long-term storage of mRNA vaccines Saswata Karmakar, Director, Platform Chemistry, Sanofi NEW DATA	11.00 Refining Lyophilization Processes to Preserve LNP Quality & Morphology for Enhanced Stability & Shelf-Life - Examining buffer choices during lyophilization to minimize impact on LNP integrity - Delving into how freeze-drying influences and changes particle structure and critical quality attributes, such as causing blebbing - Exploring optimal reconstitution methods to maintain LNP morphology and functionality for effective administration Liping Zhou, Senior Director, Advanced Drug Delivery, AstraZeneca
11.30 Session Details to Be Revealed 	11.30 Tracking the Fate of Biodegradable LNPs <i>In Vivo</i> - Highly Biodegradable lipids for LNP therapeutics are known to improve tolerability and potency - Tracking the fate of these nanoparticles in vivo poses challenges as the lipids and metabolites are labile and incompatible with conventional detection techniques - This presentation shall address our approach to solving the bioanalytical challenges and the result of metabolism and excretion studies Syed Reza, Scientific & Sales Consultant, NOF Corporation	11.30 Session Details to Be Revealed 

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS


REGISTER
NOW

Conference Day One | Tuesday, April 7

12.00 Unravelling the Intricate Interplay Between LNP-RNA Properties Influencing the Structure & Morphological Features of LNPs

- Impact of LNP composition and pKa on the LNP structure, morphology and distribution of the RNA
- Influence of the RNA cargo size on the distribution of RNA, structure and morphology of LNPs and leveraging LNP formulation process to achieve desirable LNP characteristics
- Effect of RNA modifications on the structural and morphology features of an LNPs

Lokesh Narsineni, Senior Scientist, Process Sciences, **Scribe Therapeutics**

NEW
DATA

12.00 Degradable Cyclic Amino Alcohol Ionizable Lipids as Vectors for Potent Influenza mRNA Vaccines

- Development of a new degradable ionizable lipid, AMG1541, for mRNA vaccines that significantly enhances potency and enables similar protective immunity at 100-fold lower doses than current standards, while also reducing toxicity and improving clearance *in vivo*
- Enhanced protein expression in antigen presenting cells and enhanced germinal center reactions giving rise to antigen specific B cells
- Detailed structure-activity relationship studies to unravel mechanistic aspects

Arnab Rudra, Visiting Scientist, **Boston Children's Hospital**

NEW
DATA

NEW
COMPANY

12.00 Buffer Optimization of RNA-Lipid Nanoparticles: Stability, Structure & Function Across Solution & Frozen States

- A novel mechanism for lipid tail oxidation is shown to produce degradants that react with neighbouring cargoes to form RNA-lipid adducts
- Mildly acidic, histidine-containing buffers are shown to shut down this degradation pathway and improve siRNA-LNP stability for months at room temperature
- An understanding of how buffer attributes (identity, molarity, and pH) impact mRNA-LNP structure, morphology, and transfection efficiency enables rational design of frozen storage buffers

Daniel Estabrook, Senior Advisor, Bioproduct Research & Development, **Eli Lilly & Co**

12.30 Lunch & Networking Break

Advancing Potency Assessment for Improving In Vitro/In Vivo Translation to Accelerate LNP Clinical Development

1.30 Precision RNA Delivery: AI-Guided Lipid & Nanoparticle Formulation with DNA Barcoding

- **Dual Machine Learning-Driven Optimization:** Barcode Nanotech integrates two specialized machine learning models, one for lipid design and another for nanoparticle formulation, to systematically optimize RNA delivery vehicles. This approach enables precise tailoring of LNPs to target specific cell types across diverse tissues, enhancing therapeutic efficacy and reducing off-target effects
- **High-Throughput In Vivo Screening with DNA Barcoding:** Using a proprietary DNA barcode system, Barcode Nanotech can simultaneously test up to 100 LNP formulations in a single animal. Each formulation is uniquely tagged, allowing for accurate quantification of delivery efficiency across multiple organs and cell types, accelerating discovery and validation
- **Data-Driven Formulation and Structure Insights:** The platform generates rich, multidimensional datasets that link lipid chemistry, nanoparticle architecture, and biological performance. These result in iterative design cycles, enabling the refinement of both lipid structures and nanoparticle formulations to achieve optimal RNA delivery profiles

Ronen Eavri, Chief Executive Officer & Co-Founder, **Barcode Nanotech**

NEW
COMPANY

Redesigning LNPs to Achieve Extrahepatic Targeting for Treating a Wide Array of Diseases

1.30 Engineering LNPs to Detarget the Liver by Balancing Circulation Time & Targetability for More Efficacious Drug Products

- Exploring the application of non-sheddable PEGylation to prolong systemic circulation
- Addressing the challenge of prolonging circulation whilst still maintaining efficacy and potency
- Applying targeting strategies using surface-conjugated moieties to drive tissue-specific delivery

Amit Singh, Director, Delivery Discovery, **Mote Therapeutics**

NEW
DATA

Enhancing Process Performance & Mixing Operations to Enable Consistent & Efficient LNP Production for Scalable Therapeutics

1.30 Improving LNP Manufacturing by Optimizing Process & Delving into Mixing Strategies for Consistent & Scalable LNPs

- Providing a background on process development strategies to translate LNP formulations from lab-scale to large-scale manufacturing
- Showcasing data to demonstrate how optimizing process conditions can lead to more robust, scalable LNP manufacturing
- Deep diving into mixing unit and its impact on consistent and efficient LNP manufacturing

Urmi Chheda, Senior Process Engineer, **Editas Medicines**

NEW
DATA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Conference Day One | Tuesday, April 7

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

2.00 Session Details to Be Revealed SARTORIUS 2.30 Fireside Chat: Bridging <i>In Vitro</i>/<i>In Vivo</i> Translation by Overcoming Limitations of Potency Assays & Animal Models to Accelerate Clinic Progress - What key factors should guide the selection of cell lines to develop bioassays that best predict <i>in vivo</i> LNP potency? - How to design quantitative assays that measure relevant payload expression levels for understanding biological activity? - Which animal models provide the most reliable assessment of LNP potency and how to better address variability in biodistribution and protein corona formation between species? Natalya Martin, Principal Scientist, Biochemistry & Biophysics, Analytical Development, Sanofi Bo Ying, Chief Executive Officer, Abogen Biosciences	2.00 Session Details to Be Revealed FUJIFILM Value from Innovation 2.30 Panel Discussion: Reformulating LNPs to Achieve Extrahepatic Delivery & Expand Therapeutic Reach - Which extrahepatic targets remain the greatest unmet clinical need? - What are the inherent biological challenges that are limiting LNPs from moving beyond the liver? - How to better leverage formulation and administration routes to enable effective extrahepatic targeting? Amit Singh, Director, Delivery Discovery, Mote Therapeutics Daryl Drummond, Chief Scientific Officer, Akagera Medicines Ester Caffarel-Salvador, Director, Strategic Innovation, Chiesi Global Rare Diseases Zach Zhu, Chief Technology Officer, Innorna	2.00 Session Details to Be Revealed MEPSGEN 2.30 Roundtable Discussion: Balancing Cost & Complexity for Improving Feasibility of Large-Scale Targeted LNP Manufacturing - What are the cost drivers of adding targeting steps in large-scale LNP manufacturing? - How can process development teams reduce costs while maintaining performance and product integrity? - What criteria should be used early in development to determine if a targeting strategy is commercially viable on a scale? Eric Holowka, Associate Director, Drug Delivery Innovation, Regeneron
3.00 Afternoon Networking Break & Scientific Poster Session Contribute to the conversation and share your cutting-edge research with your fellow LNP community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster* *Please visit the website for the T&Cs for presenting a poster		
Strengthening LNP Quality with Robust Analytical Strategies for Stability Testing 3.30 De-Risking LNP Stability through Advanced Analytical Strategies to Monitor Degradation & Optimize Shelf-Life - Identifying key degradation pathways and stress factors which impact LNP integrity - Establishing reliable analytical methods to monitor stability of different LNP formulations - Uncovering stability testing strategies to determine optimal storage conditions for extended shelf-life Isabelle Gusev, Principal Scientist & Group Leader, Analytical Development, CMC, Tessera Therapeutics NEW DATA	Leveraging AI-Driven Design & Ionizable-Lipid-Free Formulations to Advance RNA Delivery 3.30 An 'Irrational' Ionizable Lipid Design Approach Based on Machine Learning Models - Conventional ionizable lipid design approach is based on SAR model, innovative ionizable lipid structures are limited, SM-102 and Lipid-5 are still the benchmark for mRNA delivery - Abogen has established a library of ionizable lipids with <i>in vivo</i> test results to train our in-house machine learning model and as the model matures, we have gradually switched from rational design to AI-driven ionizable lipid generation approach - The AI-driven lipid generator has created some truly innovative structures that demonstrated superior properties not only in efficiency and safety, it may help to overcome some intrinsic limitations in LNPs during repeated i.v. dosing Bo Ying, Chief Executive Officer, Abogen Biosciences NEW DATA	Elevating TFF with Advanced Membranes & Analytical Strategies to Improve LNP Purity 3.30 Optimizing TFF by Incorporating Membrane Screening & In-Process Analytics to Enhance Buffer Exchange & Concentration - Tackling key challenges in TFF loading to guide hollow fiber vs flat sheet selection - Exploring screening strategies for membrane selection to ensure product quality during concentration and solvent removal - Walking over flux excursions and evaluation of membrane modalities for TFF of LNPs Matthew Reynolds-Tejeda, Senior Associate Scientist, Nanoparticle Process Development, Strand Therapeutics

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

REGISTER
NOW

Conference Day One | Tuesday, April 7

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

4.00 Session Reserved for Partner Enquire Here - Sponsor@hansonwade.com	4.00 Session Details to Be Revealed 	4.00 Session Details to Be Revealed 
4.30 Turning Up the Heat: DSC Unveils the Hidden Links Between Lipid Structure & LNP Morphology • Thermal Profiling for Lipids: Learning how advanced thermal characterization techniques reveal the hidden resilience - or fragility - of LNPs under different storage temperatures • Lipid Synergy & Stability Forecasting: Uncovering how lipid-lipid interactions influence formulation robustness and enable smarter predictions of long-term LNP stability • Tailoring Lipid Structure for RNA Therapeutics: Offering a predictive framework for designing effective mRNA/LNP formulations Shruti Trivedi, Scientist, Pharmaceutical Research & Development, Pfizer NEW DATA	4.30 The GENESYS™ Platform: A Novel Approach to LNP Formulation & Composition to Improve Stability, Scalability, Safety Profile, & Extra-Hepatic Targeting • Enhanced Stability & Scalable Manufacturing – Lipopeptides form highly stable particles that protect RNA during processing and storage, enabling reproducible large-scale production and simplified cold-chain logistics • Improved Safety Profile – Ionizable-lipid-free design reduces inflammatory and toxic responses, supporting repeated dosing and broad therapeutic use • Precise Extra-Hepatic Delivery – Cell-penetrating and targeting functions allow efficient uptake beyond the liver, expanding RNA therapy to cardiovascular, pulmonary, and other hard-to-reach tissues. Case study of gene therapy for use in vascular disease application enabled by GENESYS™ targeted delivery platform Jennifer Zachry, Co-Founder, Director, Business Development, Orion Therapeutics NEW COMPANY	4.30 Advancing LNP Process Development & Overcoming Challenges in Stability to Achieve Nasal Delivery • Optimizing purification strategies for bulk LNP production by comparing traditional TFF and flat-sheep membrane systems • Modifying process approaches to achieve stability and functionality for LNP formulations designed for nasal administration • Addressing scale-up and manufacturing challenges to ensure robust, reproducible production of LNPs for nasal delivery Kinkini Roy, Associate Director, Formulation & Drug Product Development, Aviceda Therapeutics
5.00 Chair's Closing Remarks		

“The conference is curated with speakers and topics that are of high impact in the field.”

Senior Scientist, Process Sciences,
Scribe Therapeutics

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS

→
**REGISTER
NOW**

Conference Day Two

Wednesday, April 8

KEYNOTE SESSION:

Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients



Annette Bak
Head, Advanced Drug Delivery
AstraZeneca



Ching Kim Tye
Head, Drug Product Platform & Early Clinical Development
Sanofi



Luis Brito
Vice President, Delivery Platform
Beam Therapeutics



Michael Smith
Director, Emerging Technologies
Moderna

Morning Plenary Session:

- ➔ Pushing the boundaries of LNP formulations to advance extrahepatic targeting

Analytical Development & Characterization Track

- ➔ Creating high-quality LNPs by leveraging analytics to assess excipients, raw materials and solvents
- ➔ Improving LNP characterization with high throughput and smarter orthogonal approaches

Formulation & Delivery Track

- ➔ Delivering gene editors with great efficacy by redefining LNP formulations
- ➔ Maximizing LNP precision, specificity and selectivity by transforming ligand design and selection

Process Development & Manufacturing Track

- ➔ Improving process control to manage particle size and de-risk batch-to-batch variability
- ➔ Accelerating bench-to-bedside translation by implementing smart scale-up strategies for LNP manufacturing

Closing Plenary Session

- ➔ Pioneering next-generation LNP platforms for accurate and safe cell therapy delivery





8.20 Registration Opens & Morning Coffee



Padma Malyala
Chief Technology Officer
nChroma Bio

8.50 Chair's Opening Remarks

Pushing the Boundaries of LNP Formulations to Advance Extrahepatic Targeting for Improved Patient Outcomes



Hongjing Xia
Principal Scientist II
Novartis

9.00 Targeted Delivery of Therapeutic Cargo to T Cells & HSC with Extrahepatic Tropism

- **Antibody-Free Targeted Delivery via LNP Engineering:** Our investigation into targeted delivery to T cells and hematopoietic stem cells (HSCs) using lipid nanoparticle (LNP) formulation modifications, supported by both *in vitro* and *in vivo* data, demonstrates the potential of antibody-free strategies for cell-specific mRNA delivery
- **Ligand- and Antibody-Mediated Targeting Approaches:** We also explored targeted delivery to T cells and HSCs using antibody or ligand conjugation methods, comparing their efficiency and specificity to non-antibody-based approaches
- **Key Observations and Insights:** We will share critical findings from both delivery strategies, including comparative performance, biodistribution, and implications for therapeutic applications



9.30 Session Reserved for ReciBioPharm

10.00 **Panel Discussion: Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients**

- What are the greatest technical challenges in translating LNP formulations from preclinic to human studies?
- Given the complexity of LNP manufacturing, scale-up, and analytical characterization, what are the critical process and regulatory bottlenecks that currently slow clinical entry?
- How can developers prioritize indications, optimize clinical trial design, and build CMC readiness to ensure more programs successfully reach patients?



Annette Bak
Head, Advanced Drug
Delivery
AstraZeneca



Ching Kim Tye
Head, Drug Product Platform
& Early Clinical Development
Sanofi



Luis Brito
Vice President,
Delivery Platform
Beam Therapeutics



Michael Smith
Director, Emerging
Technologies
Moderna



10.30 Morning Networking Break

Don't forget to enjoy some refreshments before we split off into 3 different tracks:

Analytical Development & Characterization, **Formulation & Delivery** and **Process Development & Manufacturing**

Conference Day Two | Wednesday, April 8

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

Analytical Development & Characterization	Formulation & Delivery	Process Development & Manufacturing
Chair – Peng Zhang, Principal Scientist, Science - Excipients, USP	Chair – Aishwarya Saraswat, Senior Scientist, Formulation Development Group, Regeneron	
Harnessing Analytics to Assess Excipients, Raw Materials & Solvents for High Quality LNP Products	Transforming LNP Formulations to Successfully Deliver Gene Editors with Great Efficacy	Controlling Particle Size & De-risking Batch-to-Batch Variability by Optimizing Process Parameters for Reproducible LNP Production
11.30 USP’s Evolving Approaches on Excipient Standards & Solutions Offerings in LNP Drug Development - Gain insights into iterative approaches on excipients standards and solutions to address stakeholders’ needs - Learn about the value of the standards and solutions of raw materials quality and testing - USP’s stakeholder engagement model Anni Chang, Senior Scientist II, USP	11.30 In Vivo Genome Editing: Translating Science from Bench to Bedside - Describing our expertise in metagenomics discovery and protein engineering with the help of High-Throughput Evolution Platform for Discovery and Optimization of Novel Editors (HEPDONE) system. - Introduce our proprietary lipid nanoparticle (LNP) mediated delivery systems targeting both liver and HSCs in the bone marrow - Recent clinical trial readouts from our multiple ongoing in vivo genome editing programs in China will be discussed Emma Wang, Chief Technology Officer, YolTech Therapeutics NEW DATA NEW COMPANY	11.30 LNP Particle Size Control: Effect of RNA Type, Buffer & Process Parameters - Process parameters to manipulate particle size - Influence of buffer strength on encapsulation efficiency - Comparison of particle properties between linear vs. circular mRNA – LNPs Raquib Hasan, Senior Scientist, Advanced Technologies, Drug Product Development, Takeda NEW DATA
12.00 Roundtable Discussion: Designing Quality Control Strategies to Ensure Raw Material Purity to Minimize LNP Instability - How to effectively evaluate and verify raw material purity beyond vendor specifications? - What quality control measures are essential for enzymes and excipients to ensure consistency and prevent LNP instability? - How to develop effective screening strategies for raw materials that correlate impurity profiles with LNP stability and product performance? James Deng, Associate Principal Scientist, Vaccine Analytical Research & Development, Merck & Co 	12.00 Session Details to Be Revealed CRODA Pharma 	12.00 Roundtable Discussion: Mitigating Batch-to-Batch Variability Through Reproducible Process Controls & In-Process Monitoring - What are the main process conditions and impurities driving batch-to-batch variability during LNP scale-up? - At which critical points in the manufacturing process should in-process analytics be implemented for real-time quality monitoring? - How can process controls be designed to ensure reproducibility and consistency during scale up and across batches? Padma Malyala, Chief Technology Officer, nChroma Bio 

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS


REGISTER
NOW

12.30 Engineering Next-Gen mRNA Formulations:
Maximizing Therapeutic Impact

- Formulation platform development approaches: Maximizing efficacy while minimizing side effects
- Application in vaccines: Enhancing protein expression and antibody responses
- Application in gene therapy: Enhancing editing efficacy

Saikat Manna, Senior Scientist, Delivery & Formulation, Sanofi

1.00 Lunch & Networking Break

Optimizing LNP Characterization with High
Throughput & Orthogonal Analytics for
Consistent LNPs

2.00 Analytical Characterization of Nanoparticles in Vaccine
Development

- Understanding how particle size, charge and molecular weight influence biodistribution, stability, and immunogenicity
- Leveraging SEC for the assessment of LNP homogeneity, aggregate detection, and encapsulation efficiency
- Applying DLS to characterize size distribution and polydispersity, and to monitor batch-to-batch consistency

James Deng, Associate Principal Scientist, Vaccine Analytical Research & Development, Merck & Co

NEW
DATA

NEW
COMPANY

Revolutionizing Ligand Design & Selection to
Enhance LNP Specificity & Selectivity for Precise
Targeting

2.00 Novel Targeting Strategies for Extrahepatic Delivery of
LNPs

- Inclusion of affordable small molecule targeting ligands improves delivery to innate immune cells
- Targeting impacts microdistribution of LNPs within lymph nodes following im administration
- Utility of targeted LNPs for mRNA vaccines against H5N1 avian flu and RSV

Daryl Drummond, Chief Scientific Officer, Akagera Medicines

NEW
COMPANY

Scaling Smartly by Optimizing Manufacturing for
High-Quality & Consistent LNPs

2.00 mRNA-LNP Product Development: Providing a
Roadmap to Advance from Preclinical Research to
Commercialization

- From Bench to Bedside: Optimizing LNP drug products through clinical phases to achieve scalable, regulatory compliant drug products
- Identifying differences in formulation priorities as the LNP program progresses towards later clinical development and commercialization
- Strategies for managing product comparability during process and formulation changes throughout development

Brenda Star Clemente, Director, Drug Product Process Development, Arcturus Therapeutics

NEW
COMPANY

2.30 Session Details to be Revealed



2.45 Employing High Throughput, Semi-Automated Analytical Strategies to Accelerate LNP Formulation Optimization

- The implementation of high throughput lipid content analysis to evaluate new LNP formulations
- The use of automation to streamline sample preparation and increase testing capacity without compromising data quality
- The use of 3D printing technology to accelerate automation development timelines

Natalya Martin, Principal Scientist, Biochemistry & Biophysics, Analytical Development, Sanofi

NEW DATA

2.30 Panel Discussion: Discussing Strategic Ligand Selection for a Variety of Targets to Gain Scalable & Potent Delivery

- How to identify the most suitable targeting ligand modality for a specific target?
- How to effectively and uniformly integrate the ligand onto LNP formulations?
- How to ensure the chosen ligand is viable for large-scale manufacturing?

Morgan Urello, Principal Scientist, Nucleic Acid Delivery, Biotech Startup

Saikat Manna, Senior Scientist, Delivery & Formulation, Sanofi

Matthew Eastwood, Scientist II, Nucleic Acid Delivery, Novo Nordisk



2.30 Session Reserved for Partner

[Enquire Here - Sponsor@hansonwade.com](mailto:Sponsor@hansonwade.com)

2.45 Scalable LNP Manufacturing to Advance Prime Editing for Liver Indications

- Introduction to Prime Medicine's universal liver LNP platform and formulation process
- Establishing scalable and robust unit operations to support GxP-readiness
- Key features for navigating a successful technology transfer

[Douglas Scott, Scientist II, LNP Formulations & Process Development, Prime Medicine](#)

3.15 Afternoon Networking Break

Advancing Cutting Edge LNP Platforms for Precise & Safe Delivery of Gene & Cell Therapies to Maximize Therapeutic Potential



Andrew Cornforth
Chief Technology Officer
Corner Therapeutics

4.00 DCITE: The Inside-Out Approach to Immune Modulation

NEW COMPANY

- Uncovering the delivery of cGAS-STING pathway activators via mRNA
- Effecting T-cell phenotype through dendritic cells via LNPs
- Showcasing the clinical application of DCITE for effective immunotherapies



Zach Zhu
Chief Technology Officer
Innorna

4.30 Delivering the Future: A Modular LNP Platform for Next-Gen Therapeutics

NEW DATA

- From Protein Replacement to *In Vivo* CAR: Expanding the reach of LNPs
- Translational insights from preclinical and clinical
- Enabling extrahepatic targeting and non-IV delivery across LNP designs

5.00 Chair's Closing Remarks & End of 5th LNP Formulation & Process Development Summit

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS

Take the Spotlight: Partner With Us

Your Platform to Showcase Your Exclusive Services & Build New Relationships within the Rapidly Evolving LNP Space

As the largest event dedicated to uniting LNP experts from innovative biotech and established biopharma, the **5th LNP Formulation & Process Development Summit** is the definitive forum to elevate your brand, demonstrate thought leadership and connect with a community searching for long-term partners to supercharge their LNP developments.

Benefits of Partnering:



Expand Your Client Base: With 9+ hours of dedicated networking, meet prospective clients from the likes of **AstraZeneca, Moderna, Pfizer, Novo Nordisk, Tessera Therapeutics, Sanofi** and more to unlock new commercial opportunities and partnerships.



Showcase Thought Leadership: Take the spotlight by presenting your work in one of our focused tracks, joining a panel discussion or highlighting your solutions through a bespoke exhibition booth to demonstrate your team's unique capabilities.



Benefit From Marketing Intelligence: Stay ahead of the curve by hearing directly from leading voices across the LNP field. Leverage these insights to refine your organization's strategy, tailor your offerings, and align with biopharma's evolving R&D needs.



Raise Brand Awareness & Generate Commercial Collaborations: Benefit from pre- and post-conference exposure to our global LNP community and maximize your visibility through branding, exhibition and bespoke partnership packages to help you achieve your 2026 business goals.

Our Audience are Looking for Partners Including:



CDMO



Lipid Suppliers



Analytical & Process Development Equipment



Formulation & Synthesis



Particle Engineering & Characterization



Imaging & Bioinformatics




Structure-Based Modelling



Delivery, Device & Fill

SENIORITY OF ATTENDEES*



Chief/CxO – 9%

VP, Head – 10%

Director – 18%


Team Lead, Manager – 12%

Scientist – 35%

Research, Professor – 5%

Other – 11%

TYPES OF COMPANIES ATTENDING*



*Statistics taken from 4th LNP Formulation & Process Development Summit

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

2026 Expert Partners

5th Annual
LNP Formulation &
Process Development Summit
April 6-8, 2026 | Boston, MA

REGISTER BY
FRIDAY,
DECEMBER 5
& SAVE UP TO
\$900

Lead Partner



Expertise Partner



Program Partner



Innovation Partner



Exhibition Partner



CONTENTS

INTRODUCTION

AGENDA AT A
GLANCE

YOUR EXPERT
SPEAKERS

PRE-
CONFERENCE
DAY

CONFERENCE
DAY ONE

CONFERENCE
DAY TWO

PARTNER WITH
US

PRICING &
DISCOUNTS



REGISTER
NOW

Ready to Register?

3 Easy Ways To Book

 lnp-formulation-process-development-pharma.com/register/

 Tel: +1 617 455 4188

 Email: info@hansonwade.com

Team Discounts*

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

*Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.
Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.
Contact: register@hansonwade.com

- ① **Unparalleled** access to LNP industry leader’s insights from **Moderna, AstraZeneca, Novo Nordisk, Alnylam** and **Pfizer** to guide your pipeline direction
- ② **Network** with **250+ LNP experts** bound by the same challenges and hurdles across Analytical Development, Formulation, Process Development and Manufacturing
- ③ **Divide** and conquer 3 days of content and a 3 track program spanning the end-to-end development of LNPs, from discovery through to clinic
- ④ **Showcase** your breakthroughs during the scientific poster session and spark fresh perspectives from industry peers driving the future of LNP science

Drug Developer Pricing **	Register & Pay By Friday, December 5	On the Door Price	Academic Pricing ***	Register & Pay By Friday, December 5	On the Door Price	Solution Provider Pricing	Register & Pay By Friday, December 5	On the Door Price
Conference + Pre-Conference Day	\$3,297 (Save \$900)	\$4,197	Conference + Pre-Conference Day	\$2,697 (Save \$900)	\$3,597	Conference + Pre-Conference Day	\$4,297 (Save \$900)	\$5,197
Conference Only	\$2,499 (Save \$500)	\$2,999	Conference Only	\$2,099 (Save \$500)	\$2,599	Conference Only	\$3,299 (Save \$500)	\$3,799

**To qualify for the drug developer rate your company must have a public drug pipeline and not offer fee-based services.
***To qualify for academic rate you must be full time academic. Do you work for a Not-for-Profit organization? Please visit the website for full pricing options or email info@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities, tag, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

Venue

The Westin Boston Seaport District

425 Summer Street, Boston, MA 02210, United States

www.marriott.com/en-us/hotels/bosow-the-westin-boston-seaport-district/overview/

REGISTER BY FRIDAY, DECEMBER 5 & SAVE UP TO \$900

CONTENTS

INTRODUCTION

AGENDA AT A GLANCE

YOUR EXPERT SPEAKERS

PRE-CONFERENCE DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PRICING & DISCOUNTS

→

REGISTER NOW